The Technical Analyst
Structure Therapeutics [GPCR]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Structure Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.63% $39.99
/ 7 mai 2024 @ 12:57
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 863.46 mill |
| EPS: | -2.43 |
| P/E: | -16.46 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 46.60 mill |
| Avg Daily Volume: | 0.593 mill |
| RATING 2024-05-07 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -16.46 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -16.46 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.38 (-91.54%) $-36.61 |
| Date: 2024-05-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 37.42 - 42.05 ( +/- 5.83%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-17 | Fmr Llc | Buy | 0 | |
| 2024-03-15 | Lin Xichen | Buy | 213 486 | Stock Option (right to buy) |
| 2024-03-15 | Bach Mark Allen | Buy | 65 352 | Stock Option (right to buy) |
| 2024-03-15 | Ma Yingli | Buy | 91 494 | Stock Option (right to buy) |
| 2024-03-15 | Yoon Jun | Buy | 148 134 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 30.54 |
| Last 43 transactions |
| Buy: 9 065 015 | Sell: 6 065 489 |
Forecast:
14:37 - $40.00
Live Trading Signals (every 1 min)
Forecast
1: 13:07 - $39.94
Forecast 2: 13:57 - $39.98
Forecast 3: 14:37 - $40.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $39.99 (0.63% ) |
| Volume | 0.141 mill |
| Avg. Vol. | 0.593 mill |
| % of Avg. Vol | 23.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GPCR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:31 | buy | $48.29 | N/A | Active |
|---|
GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-03-08 16:05:00 - Press Release
Structure Therapeutics To Present At Leerink Partners Global Biopharma Conference
San francisco, march 08, 2024 (globe newswire) -- structure therapeutics inc. (nasdaq: gpcr), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that raymond stevens, ph.d., the company's founder and chief executive officer, will participate in a fireside chat at the leerink partners global biopharma conference on wednesday, march 13, 2024, at 8:00 am et in miami, florida.
2024-03-08 08:30:00 - Press Release
Structure Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Highlights
Topline gsbr-1290 phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024
2023-12-18 07:30:00 - Press Release
Structure Therapeutics Provides Comprehensive Gsbr-1290 Program Update Including Clinically Meaningful Proof-of-concept Data From Phase 2a Clinical Study
Gsbr-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% study discontinuation rate due to adverse events in obesity
2023-11-14 16:10:00 - Press Release
Structure Therapeutics Reports Third Quarter 2023 Financial Results And Recent Highlights
Announced positive results from phase 1b clinical study of oral glp-1 receptor agonist, gsbr-1290, demonstrating significant weight loss supporting once-daily dosing and an encouraging safety and tolerability profile
2023-09-29 07:32:00 - Press Release
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors
Latest News
2024-05-07 11:33:29 - CNBC
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
2024-04-24 06:33:00 - InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.
2024-04-16 19:09:00 - Market Watch
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
2024-03-30 09:37:14 - InvestorPlace
7 Small-Cap Stocks that Wall Street Loves for Good Reason
With the major indexes at or near record highs, it's been easy to overlook the performance of the small-cap Russell-2000 Index. While the index is “only” up about 5% in 2024, it's up 21% in the past 12 months, and is slowly starting to catch up to the market rally.
2024-03-09 02:30:00 - Barrons
Wegovy and Zepbound Are King. Who's Coming for Their Crowns.
Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.
2024-03-08 16:05:00 - GlobeNewsWire
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that Raymond Stevens, Ph.D., the Company's Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.
2024-01-17 15:40:55 - CNBC
The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space
Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.
2024-01-08 07:03:12 - MarketBeat
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY.
2023-12-25 07:45:00 - The Motley Fool
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
Structure Therapeutics stock declined sharply due to some data it published. The data show that its flagship drug candidate appears to be safe and effective.
2023-12-22 16:21:22 - InvestorPlace
7 Small-Cap Stocks That Wall Street Loves for Good Reason
As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.